ORG Partners’s Prime Medicine PRME Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q3
Sell
-5,270
Closed -$28.9K 1326
2024
Q2
$28.9K Buy
+5,270
New +$31.9K ﹤0.01% 977
2024
Q1
Sell
-5,270
Closed -$46.7K 935
2023
Q4
$46.7K Hold
5,270
0.01% 530
2023
Q3
$50.3K Hold
5,270
0.01% 518
2023
Q2
$76.4K Buy
+5,270
New +$73.6K 0.01% 583

Other funds holding PRME

ORG Partners's PRME Position: Q3 2024 in Review

ORG Partners sold out of Prime Medicine (PRME) in Q3 2024, closing a stake of 5,270 shares — an estimated $28.9K sold.

ORG Partners first reported a position in PRME in Q2 2023 and held it in 4 quarters. The position peaked at $76.4K in Q2 2023. 116 funds tracked by Wall St. Rank hold PRME as of Q3 2024.

  • ORG Partners reported no remaining Prime Medicine position as of Q3 2024 after selling out during the quarter.
  • ORG Partners sold 5,270 Prime Medicine shares in Q3 2024, an estimated $28.9K.
  • ORG Partners first reported a position in Prime Medicine in Q2 2023 and held it in 4 quarters.
  • ORG Partners's Prime Medicine position peaked at $76.4K in Q2 2023.
  • 116 funds tracked by Wall St. Rank held Prime Medicine as of Q3 2024.

Based on ORG Partners's 13F filing for Q3 2024, filed 11 Oct 2024.